A sourcing mandate that lands as a margin cut
The in-office infusion suite has never been funded by its administration codes alone. It is funded by the spread on the drug. Under the traditional buy-and-bill model, the practice purchases an agent such as infliximab or rituximab at an acquisition cost referenced to average sales price, administers it, and bills the medical benefit for both the drug — typically at an ASP-plus rate — and the administration. That drug margin is what covers the real cost of running the suite: pharmacist and nursing time, chair capacity, storage and handling, inventory carrying cost, payer follow-up, and the ever-present risk of waste. Remove the drug from the practice’s books and the administration fee is left to carry a cost structure it was never sized to support.
That is precisely what a white bagging mandate does. The practice still schedules the patient, staffs the chair, and assumes the clinical risk of administration — but the drug revenue, and the margin inside it, moves to the PBM’s pharmacy. As the National Infusion Center Association puts it plainly, under a white bagging requirement infusion providers are left administering complex therapies “without proper reimbursement.” The mandate is framed as a change in where a drug comes from. It functions as a change in who keeps the margin.
White bagging is not, at root, a pharmacy problem to be litigated drug by drug. It is a contracting problem. The practice that quantifies its true cost-to-administer, maps the mandate by payer and plan type, and negotiates buy-and-bill protection into the agreement keeps control of the economics. The practice that treats it as an operational inconvenience absorbs a margin cut it never agreed to.
Why the model breaks — and where the cost goes
The same infusion, delivered to the same patient in the same chair, produces materially different practice economics depending on who sources the drug. The comparison below isolates that mechanism.
The buy-and-bill spread is the cross-subsidy — white bagging removes it and leaves the cost
Illustrative structure for a single high-cost biologic infusion. Values are conceptual, not benchmarks; the point is the direction, not the dollars.
Buy-and-Bill (medical benefit)
The drug spread offsets nursing, chair time, storage, carrying cost, and waste risk. The service sustains itself.
White Bagging (pharmacy benefit)
Drug revenue moves to the PBM pharmacy; the practice keeps the cost and absorbs patient-specific waste and delivery risk.
Fulcrum Health Partners analysis. White bagging also introduces costs the medical debate often omits: patient-specific dispensing prohibits last-minute dose adjustment and forbids reallocating an unused drug to another patient, so clinical waste becomes practice friction, and “just-in-time” delivery exposes the schedule to shipment delay.
Two implications follow for rheumatology specifically. First, the specialty is unusually exposed: rheumatologists administer a high volume of specialty biologics and are far more likely than most office-based physicians to hold their own inventory and rely on buy-and-bill, so the margin at risk is proportionally larger. Second, the clinical and economic harms compound. The ACR has emphasized that buy-and-bill exists partly because it allows dose adjustment up to the moment of infusion; a patient-specific white-bagged drug removes that flexibility, and any unused portion is wasted rather than recovered. The practice therefore loses margin and absorbs new operational cost at the same time.
The right question for a rheumatology group is not “can we still get the drug?” It is “what is our fully loaded cost to administer, and is the payer proposing to pay for the service once the drug margin is gone?” Until that number is known, the practice cannot tell whether a given mandate is survivable or simply a subsidy transfer to the PBM.
Contract levers before concessions
A white bagging mandate is rarely all-or-nothing, and it is rarely uniform across a practice’s payers. The levers below are ordered from strongest to most defensive; most groups have more room than they assume, particularly where infusion volume gives them network relevance.
Protect buy-and-bill in the contract language
The cleanest protection is explicit: preserve the practice’s right to source and bill provider-administered drugs under the medical benefit, and require mutual agreement before any white or brown bagging is imposed. Where a payer resists a prohibition, a carve-out for high-cost biologics or a right to opt out on clinical grounds achieves much of the same effect.
Set a reimbursement floor for what remains
If some white bagging is unavoidable, the administration service must be repriced to stand on its own. That means an explicit ASP-plus floor on drugs still bought and billed, and administration and handling fees benchmarked to the fully loaded cost of the suite — not the legacy fee that assumed a drug spread underneath it.
Use the state-law and plan-type backdrop
A dozen states have moved to restrict mandatory white bagging, and more are debating it. Those protections generally reach fully insured plans but not self-funded ERISA plans, so the same employer’s members may be treated differently. Knowing which of a payer’s books the mandate can lawfully touch is a negotiating fact, not a footnote — issues of legal applicability should be confirmed with counsel.
Make network relevance and safety part of the case
Where the practice supplies infusion capacity a payer’s network cannot easily replace, access and continuity are leverage. The documented risks of delivery delay, mishandling, and lost dose flexibility strengthen a clinical-safety position that payers increasingly must answer to.
Before you concede the infusion suite
Quantify cost-to-administer
Establish the fully loaded cost per infusion — nursing, chair, storage, carrying cost, waste, and follow-up.
Map the exposure
Which drugs, which payers, and which plan types (fully insured vs. self-funded ERISA) does the mandate actually reach?
Model the margin at risk
Quantify the drug spread that would move to the PBM and the residual on the administration service alone.
Negotiate protection or a floor
Secure buy-and-bill language, a carve-out, or a repriced administration fee that stands without the drug margin.
Decide deliberately
Protect, adapt, or selectively exit — on evidence, not by default, and payer by payer rather than across the board.
Sourcing is the payer’s argument. Economics is yours.
Payers will continue to advance white bagging as a cost-control and safety measure, and in some markets and plan types they have the contractual footing to do so. A rheumatology practice does not have to accept the framing. The mandate’s real effect is to move a margin that has quietly funded the infusion suite for years, and the practice’s strongest response is to make that transfer explicit — to arrive at the table with a defensible cost-to-administer, a clear map of where the mandate can and cannot apply, and specific contract language rather than a general objection.
Handled that way, white bagging becomes one more term to be negotiated on evidence. Handled passively, it becomes a standing subsidy to the payer’s pharmacy, paid for out of a service the practice is still expected to provide. The difference is not clinical conviction; it is contracting discipline.
Sources
- National Infusion Center Association, “White Bagging” issue overview and “Payer White-Bagging Requirements: Considerations for Access to Infusion Care.”
- The Rheumatologist (ACR/ARP), “Trends in State White Bagging Legislation” — mechanics, waste, dose-flexibility, and state activity.
- American Medical Association / ASCO, issue brief on mandatory white and brown bagging and patient-access safety; AMA state advocacy updates (2025) on states restricting white bagging.
- AHIP, Brown & White Bagging State Law Chart — plan-type applicability and state status.
- Avalere Health and ICER white papers on infusion care, white/brown bagging, and site-of-service economics.